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PENILAIAN FUNGSI FLAG-STAT1B DI SEL U3A 
 
 
 
 
ABSTRAK 
 
 
 
 
Wabak penyakit seperti SARS, Ebola dan Zika bukan sahaja membawa kesan negatif 
kepada ekonomi dan sosial global, juga kesihatan manusia dan nyawa yang berharga. 
Peranan imuniti adalah penting untuk perlindungan kesihatan. Interferon (IFN) jenis I yang 
terdiri daripada IFN-α dan IFN-β dihasilkan oleh imuniti semula jadi semasa jangkitan 
virus melalui interaksi host-patogen. IFN mencetuskan respons IFN yang menyumbang 
kepada akitivi antivirus melalui laluan isyarat intraselular Janus kinase-signal transducer 
and activator of transcription (JAK-STAT) termasuk komponen utamanya, STAT1. 
Manusia STAT1 terdapat dua isoform iaitu STAT1A yang panjang sepenuh dan variasi 
split STAT1B yang kekurangan sebahagian domain pengaktifan transkripsi. Kepentingan 
STAT1 dalam imuniti telah terbukti oleh tikus fenotip Stat1-/- yang lebih terdedah kepada 
jangkitan virus. Permahaman yang lebih lanjut terhadap laluan intraselular JAK-STAT dan 
STAT1 dengan respons interferon mampu menambah pengetahuan mengenai interaksi 
host-patogen dalam imuniti semula jadi. Ini mendorong projek kami sebagai kajian awal 
yang bertujuan menyiasat keupayaan rekombinan Flag-STAT1B di sel U3A dalam 
mengembalikan respons IFN melalui laluan JAK-STAT. Plasmid rekombinan         
p3xFlag-STAT1B yang dihasilkan telah menghantar kepada sel U3A.  
xvi 
 
IFN-β telah digunakan untuk mengekspresikan sel-sel. Penyelidikan ekspresi STAT1 dan 
interferon stimulated genes (ISGs) di sel U3A dilengkapi Flag-STAT1B telah dilaksanakan 
melalui immunoblot dan ImageJ digunakan untuk analisis kuantitatif. Kawalan posited 
adalah sel 2fTGH (STAT1A dan STAT1B) yang mendapat laluan JAK-STAT yang 
sempurna. Ekspresi ISGs dalam kajian ini menunjukkan pembaikan laluan isyarat JAK-
STAT. Tetapi, eskspresi ISGs tidak dikompensasikan sepenuhnya kalau berbanding dengan 
sel 2fTGH. Hasil kajian ini adalah sel U3A dilengkapi STAT1B boleh memulihkan laluan 
isyarat JAK-STAT dengan sebahagian ekspresi ISGs semasa IFN-β dibagikan. Kajian ini 
mampu membawa kepada kemungkinan baharu untuk mekanisme STAT1 isoforms dalam 
laluan isyarat JAK-STAT dan respons IFN.   
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FUNCTIONAL EVALUATION OF FLAG-STAT1 IN U3A CELLS 
 
 
 
 
ABSTRACT 
 
 
 
 
Viral infections have had massive socio-economic impact, at the costs of human health and 
invaluable lives. However, effective and broad spectrum protection against viruses is still 
lacking despite best efforts. Antiviral immune defense is crucial for host protection in the 
event of viral infections. Type I interferons (IFN), are key mediators for antiviral immunity, 
and are induced following recognition of viral-associated molecular patterns. Type I IFNs 
released to the extracellular matrix then help establish antiviral state at the cellular level in 
autocrine and paracrine manner. Signaling by Type I IFNs is transduced via Janus kinase-
signal transducer and activator of transcription (JAK-STAT) pathway, leading to 
upregulation of interferon stimulated genes. STAT1 is a key component of the JAK-STAT 
signaling pathway, where two major isoforms: STAT1A and STAT1B are naturally 
expressed during Type I IFN response. STAT1 is essential in antiviral immunity as Stat1-/- 
mice are more susceptible to virus infection. However, the possibly of distinct roles of 
STAT1 isoforms in antiviral immunity warrants further investigation for more 
comprehensive understanding of the JAK-STAT pathway towards developing protection 
against viruses. This project thereby serves as groundwork in preparation for future 
research on STAT1 isoforms and their cellular functions. We aim to establish an essay 
xviii 
 
involving the expression of a functional recombinant Flag-STAT1B in U3A cells, a cell 
line lacking endogenous STAT1 that is derived from 2fTGH cells. Therefore, expression 
plasmid for recombinant Flag-STAT1B was constructed by sub-cloning. The expression 
plasmid was transfected into U3A cells and Flag-STAT1B was successfully expressed. 
When the transfected cells were challenged with IFN-β, recombinant Flag-STAT1B 
partially restored the previously dysfunctional JAK-STAT signaling pathway in U3A cells. 
Protein expression levels of several interferon stimulated genes were semi-quantitatively 
analyzed through immunoblotting and ImageJ. From our results, overexpression of 
STAT1B without STAT1A in U3A cells could not fully restore the JAK-STAT signaling 
pathway. While more research is necessary, our work suggest that the different STAT1 
isoforms may have overlapping but yet distinct roles at the cellular level during Type I 
interferon response. Further investigation may lead to novel understanding about the 
mechanism of STAT1 isoforms and their impact on host antiviral immunity.  
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CHAPTER 1: INTRODUCTION 
1.1  Background 
Over the past two decade, viral outbreaks such as Zika, Ebola, Middle East respiratory 
syndrome (MERS), severe acute respiratory syndrome (SARS), avian flu virus has 
dominated headlines and captured the public attention. SARS epidemic outbreak origin 
from southern China have spread globally and over 8000 cases had reported in 37 countries 
from 2002-2013. Avian influenza virus have transmit from Asia to Africa and Europe since 
2003 and re-emerging in China in 2017 involving avian influenza A(H7N9) virus. MERS 
cause by MERS coronavirus first reported in Saudi Arabia at 2012 had spread to several 
countries included Malaysia. Recent Ebola virus outbreak in West Africa and Zika virus 
disease outbreak that causes fetal neurological disease (World Health Organization, 2017; 
Centers for Disease Control and Prevention, 2017).  
On the other hand, despite concerted effort from the biomedical community, proper cure 
from disease chronic viral infections like acquired immune deficiency syndrome and 
Hepatitis has not been found, though disease management has been improved. All of these 
showed the inadequate understanding of viral-host interaction. To prevent future emerging 
viral outbreaks and to manage persistent virus infections, it is necessary for further research 
on both viruses and human immune system, and their interactions.  
Immunity system in human can be generally divided into innate and adaptive immunity. 
Innate immune response is less specific against pathogens. Cellular components of innate 
immunity are ready prior to infection and can be activated rapidly for onset of immune 
defense. On the other hand, adaptive immune response is slower but more specific, as 
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lymphocytes activation and antibody production are driven by encountered antigen. Both 
innate and adaptive immune system are communicative and heavily interlinked (Koyama et 
al., 2008).  
 
1.2 Innate Immunity 
Host innate immunity plays a vital role as rapid first line defense against viral infection 
before the slow onset of adaptive immune system. Host innate immunity on self can 
distinguish between “self” and “non-self” biomolecules. Immune cells involved innate 
immunity including natural killer cells, phagocytic cells and inflammatory cells. An innate 
immunity response is elicited upon recognition of pathogen-associated molecular patterns 
(PAMPs) by pattern-recognition receptors (PRRs) (Noakes and Michaelis, 2013). Toll-like 
receptors (TLRs) are either expressed on cell membrane or associated with intracellular 
vesicles that enable both extracellular and cytoplasmic recognition of the PAMPs. Retinoic 
acid-inducible gene I-like receptors (RIG-I-like receptors) and nucleotide-binding 
oligomerization domain-like receptors (NOD-like receptors) are involved in cytoplasmic 
PAMPs detection (Nakhaei et al., 2009). Distinct PAMPs derived from viruses, bacteria, 
mycobacteria, fungi and parasites are detected by specific PRRs. For example, viral DNA 
is recognized by TLR9 whereas viral RNA cache detected by TLR3, TLR7 and TLR8. 
Activation of PRRs will then leads to signaling cascade adaptor proteins and induce Type I 
Interferon (IFN) or pro-inflammatory cytokines production (Kawai and Akira, 2010, 
Nguyen et al., 2016). Type I IFN then induce IFN response via Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) signaling pathway.  
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1.3 Interferon (IFN) 
IFN was first discovered in 1957, based on its ability to interfere with the life cycle and 
replication of influenza virus in chick embryo cells (Isaacs and Lindenmann, 1957). After 
that, subsequent studies revealed many different types of IFNs. IFNs have antiviral 
properties, plays a role in bridging innate and adaptive immunity and regulate cell cycle 
(Mossman, 2011). Human IFN could be classified into 3 classes: Type I, Type II and Type 
III. Type I IFN comprised of IFN-α and IFN-β are the principle cytokines mediating 
antiviral response and can be expressed by all nucleated cells upon viral infection (Koyama 
et al., 2008). IFN-γ is the only Type II IFN, secreted by natural killer cells and T cells 
responsible for immunoregulatory in innate and adaptive immunity (Saha et al., 2010). 
Type III IFNs, such as IFN-λ1, IFN-λ2 and IFN-λ3 has been discovery recently to possess 
antiviral properties as well. Induction of IFN-λ are independent on IFN regulatory factor 
(IRF) and nuclear factor-kappaβ (Iversen and Paludan, 2010). IFNs induce interferon 
stimulated genes (ISGs) via JAK-STAT signaling pathway. 
 
1.3.1 Induced expression of Type I interferon  
Distinct viral constituents are recognized by various PRRs including TLRs and RIG-I-like 
receptors (Figure 1.1). TLR3 recognizes extracellular viral double-stranded RNA (dsRNA), 
TLR7 and TLR8 recognizes viral single-stranded RNA (ssRNA) whereas TLR9 detects 
viral DNA contains CpG-motifs (Blasius and Beutler, 2011, Kawai and Akira, 2011).  
Activated TLRs can induce Type I IFN production via signaling cascade involving TIR-
domain-containing adapter-inducing interferon-β (TRIF) and myeloid differentiation 
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primary response 88 (MyD88) (Piras and Selvarajoo, 2014). Cytoplasmic viral ssRNA and 
dsRNA can also be recognized by RIG-I-like receptors such as retinoic acid-inducible gene 
I receptors (RIG-I) and melanoma differentiated-associated protein 5 (MDA5), eventually 
leading to IFN-α/β expression via downstream cascade involving mitochondrial antiviral 
signaling protein (Dixit and Kagan, 2013).  
 
 
Figure 1.1: A schematic diagram of viral nucleic acids recognition by pattern 
recognition receptors. Viral nucleic acid can be detected by Toll-like receptors, RIG-I like 
receptors, NOD-like receptors and intracellular DNA receptors. Detection of viral 
constituents induces Type I IFN production and response to viral infection. [Figure is from 
(Crouse et al., 2015)]. 
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1.3.2 Type I interferon response 
ISGs is quiescent and has low basal expression in general for unstimulated cells. 
Expression of ISGs can be induced by Type I IFN via JAK-STAT intracellular signaling 
pathway (Figure 1.2). Collectively, expression of ISGs with establish antiviral response in 
host cells (Leaman et al., 1998). Type I IFN to interferon alpha receptors (IFNARs) 
receptors for Type I IFN ligand composed of IFNAR1 and IFNAR2 subunits, associated 
with kinases tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) respectively. Binding of 
IFNARs will trigger dimerization of receptors that further activates JAK1 and TYK2. 
Activated JAK1 and TYK2 then phosphorylate tyrosine residue on IFNARs and in turn 
mediate the recruitment of signal transducer and activator of transcriptions 1 (STAT1) and 
signal transducer and activator of transcriptions 2 (STAT2) via their SH2 domains 
(Schindler et al., 1992, Darnell et al., 1994). Next, phosphorylation of the recruited STAT1 
and STAT2 will lead to formation of STAT1/STAT2 heterodimers. STAT1/STAT2 dimers 
associated with interferon regulatory factor 9 (IRF9) to form interferon stimulatory gene 
factor 3 (ISGF-3), a potent transcription factor that translocates into the nucleus. ISGFs 
binds to IFN-stimulated response elements (ISRE; AGTTTNNNTTTCC) in the promoter 
region of many ISGs, promoting transcription of those ISG (Schindler et al., 1992, 
Schindler et al., 2007). ISGs included ADAR1, PKR, MX1, OAS1 and also gene involved in 
JAK-STAT signaling pathway such as STAT2 and IRF9. 
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Figure 1.2: Schematic diagram depicting Type I IFN response through JAK-STAT 
signaling pathway. (1) Binding of Type I IFN stimulates dimerization of IFNAR1 and 
IFNAR2. (2) Activated IFNAR transphosphorylate TYK2 and JAK1. (3) Phosphorylated 
Janus kinases (JAKs) in turn phosphorylate tyrosine residues on IFNARs, (4) which 
provide docking site to STAT2. (5) STAT2 subsequently phosphorylated by JAKs. It 
recruits and activates STAT1 leading to STAT1/STAT2 dimerization. (6) STAT1/STAT2 
dimers together with IRF9 formed ISGF3, translocate into nucleus and bind to IFN-
stimulated response elements (ISRE) for ISGs expression. [Figure is from (Suprunenko and 
Hofer, 2016)]. 
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1.4  JAK-STAT signaling  
The JAK-STAT is an important intracellular signaling pathway in response to various 
cytokines. Different combination of JAKs and signal transducer and activator of 
transcriptions (STATs) are activated in response to different ligands (Figure 1.3). For 
example, IFN-R family activates STAT1, STAT2, STAT3 and STAT5 whereas IL-3R 
family only activates STAT5 (Figure 1.3). The pathway transduces information from the 
extracellular environment to the nucleus by STATs dimer translocation and stimulates 
corresponding gene expression in accordance to the extracellular signal. As such, JAK-
STAT signaling is vital for fundamental cellular process such as cell proliferation, 
differentiation, apoptosis, immunity development, hematopoiesis and homeostasis 
(Rawlings et al., 2004, Pfitzner et al., 2004, Song et al., 2011, Coskun et al., 2013). 
 
1.4.1 JAKs 
The four members of JAKs family, JAK1, JAK2, JAK3 and TYK2 range in sizes between 
120-140 kDa. JAKs are composed of seven conserved JAK homology (JH) domains 
(Figure 1.4A), where JH1 and JH2 are kinase domains responsible for phosphorylation of 
receptors and STATs. Meanwhile, the N-terminal domains (JH4-JH7) mediates interaction 
with receptors and JH3 binding to phosphorylated tyrosine (Schindler et al., 2007, Coskun 
et al., 2013). 
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1.4.2 STATs 
STATs family comprised of seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, 
STAT5B and STAT6. Sizes of STATs range from 750-900 amino acids and consist of 
seven conserved domains (Figure 1.4B). All the conserved STAT1 domains are known for 
distinct functions, where: the N-terminal (NH2) domain is important in STATs dimerization 
at inactive state; the hydrophilic surface of coiled-coil domain is critical for regulators 
binding; the DNA-binding domain determines the DNA binding specificity in the nucleus; 
the SH2 domain crucial in STAT recruitment to the activated receptors and dimerization; 
the tyrosine activation domain at around 700 amino acid residues; and C-terminal 
transcription activation domain (TAD) involved in driving transcription through 
association with transcriptional regulators (Hoey and Schindler, 1998, Schindler et al., 
2007). 
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Figure 1.3: JAK-STAT signaling pathway. Different JAKs and STATs are involved in 
mediating signals from different cytokines. STATs dimer or associated with regulator 
translocate into nucleus, binds to IFN-stimulated response elements (ISRE) and simulate 
interferon stimulated genes (ISGs) transcription. [Figure is from (Coskun et al., 2013)]. 
 
 
 
Figure 1.4: Conserved domain for JAKs and STATs. (A) General structure of JAKs, 
consists of seven JH domains, JH1-7. (B) Structure of STAT with seven conserved 
domains including amino-terminal (NH2) domain, coiled-coil domain, DNA binding 
domain (DBD), linker domain (LK), SH2 domain, tyrosine activation domain and 
transcription activation domain (TAD). [Figure is from (Schindler et al., 2007)]. 
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1.5  STAT1 
Transcriptional activation studies following exposure to IFN established a multitude of 
expressed genes (ISGs). A consensus sequence (ISRE) was discovered at the promoter 
region of ISGs, and the corresponding transcriptional factor was identified as ISGF-3. 
Protein purification revealed that ISGF-3 is a protein complex with four proteins with sizes 
113, 91, 84, 48 kDa, respectively. The proteins were named subsequently STAT1A (p91), 
STAT1B (p84) and STAT2 (p113) due to their dual function as signal transducers and 
activators of transcription, whereas p48 was later identified as IRF9. STAT1 and STAT2 
were the first identified STAT proteins (Shuai et al., 1992, Schindler et al., 1992).  
STAT1 activation by phosphorylation at tyrosine 701 can be induced by various ligands 
such as IFN, platelet-derived growth factor, IL-6 and IL-12. Activated STAT1 will then 
form heterodimer under most circumstances, except in response to  IFN-γ that leads to 
STAT1 homodimerisation in turn binding to IFN-gamma-activated sequence (GAS) in the 
nucleus (Wegenka et al., 1994). There are two natural isoforms of STAT1, the full length 
STAT1A (750 amino acids) and smaller split variant STAT1B (712 amino acids). STAT1B 
lacks the last 38 residues within the TAD, compared to STAT1A (Figure 1.5). The 
variation arise from alternative splicing event, where STAT1A mRNA has 25 exons while 
STAT1B mRNA only has 23 spliced exons (Darnell et al., 1994, Chapgier et al., 2009). 
STAT1B that lacks part of the TAD is unable to bind to E1A binding protein p300-CREB 
binding protein (p300-CBP) coactivator family (Zhang et al., 1996).  
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Figure 1.5: Schematic diagram depicting of STAT1A and STAT1B. [Figure is from 
(Chapgier et al., 2009)]. 
 
1.5.1  STAT1 in innate and adaptive immunity 
STAT1 is one of the key mediators in IFN response for antiviral immunity. The importance 
of STAT1 in immunity is apparent from the analysis of in vivo STAT1 deficient mice or by 
clinical cases. Stat1-/- mice showed compromised innate immune response and are 
susceptible to viral infection such as vesicular stomatitis virus (VSV) infection and herpes 
simplex virus type 1 (HSV-1), compared to Stat1+/+ mice (Durbin et al., 1996, Pasieka et al., 
2008). Patients with fatal combined immunodeficiency that displayed progressive 
destruction of lymphocytes and autoimmune disorders has been associated with 
heterozygous mutation of STAT1 with reduced STAT1 expression level (Sharfe et al., 
2013). In another study, heterozygous STAT1 gain-of-function mutation is associated with 
development of systemic or atypical viral infection (38%), chronic mucocutaneous 
candidiasis (98%) and bacterial infections (74%) (Toubiana et al., 2016). 
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1.5.2 STAT1 in haematopoiesis 
Haematopoiesis or haemopoiesis describe the formation of blood cells, including formation 
of erythrocytes (erythropoiesis), platelet (thrombocytosis), lymphocytes (lymphocytosis) 
and granulocytes and monocytes (myelopoiesis). Site of haematopoiesis varies at different 
stage of growth, including yolk sac, liver, spleen and bone marrow at fetal state; all bone 
marrows during infancy; and at bone marrow of only central bones during adulthood. 
Besides, thymus, spleen and lymph nodes are also involve in maturation and proliferation 
of blood cells. All blood cells are derived from pluripotent haematopoietic stem cell (HSC). 
Differentiation, maturation and proliferation of different lineage progenitor cells and 
mature blood cells are regulated by haematopoietic growth factors (Hoffbrand and Moss, 
2011).  
STAT1 in hematopoiesis regulation have been demonstrated in various STAT1 deficient 
models.  STAT1 deficient mice showed 1.6 fold reduction in of total body colony forming 
unit-erythroid, delayed differentiation and increased apoptosis of early erythroblasts in 
bone marrow (Halupa et al., 2005). The importance of STAT1A and STAT1B in zebrafish 
embryonic hematopoiesis was studied by Song, et al. (2011), which revealed distinct roles 
for the isoforms in hematopoiesis. Knockdown of stat1b in zebrafish embryo led to 
increased scl (hematopoietic progenitor marker), denser gata1 (erythrocyte marker) and 
increased hemoglobin-producing cells compared to stat1a knockdown and control without 
stat1 knockdown (Song et al., 2011). 
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1.5.3 STAT1 in myeloproliferative neoplasms (MPNs) 
Myeloproliferative neoplasms (MPNs) are hematological malignancies characterized with 
overproduction of blood cells either erythrocyte, leukocyte, thrombocyte or granulocyte 
which can brings significant morbidity and mortality (Tefferi and Vardiman, 2008). MPN 
patient suffer from fatigue, pruritus, night sweats and bone pain (Mesa et al., 2007). 
Hematopoietic tumor disorders classified under MPNs include chronic myelogenous 
leukemia (BCR-ABL1-positive), chronic neutrophilic leukemia, polycythemia vera (PV), 
primary myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic 
leukemia (not otherwise specified), myeloproliferative neoplasms (unclassifiable) and 
mastocytosis (Vardiman et al., 2009). Mutation or genetic changes in hematopoietic stem 
cell is the main reason for MPNs, by causing gain of multilineage differentiation ability 
and myelopoiesis. JAK2, MPL, TET2, ASCL1, IDH1, IDH2, CBL, IKZF1, LNK and EZH2 
are known mutation associated with MPNs (Tefferi and Vainchenker, 2011). In PV, ET and 
PMF, the most prevalent mutation recognized in these three MPNs is JAK2V617F, found in 
about 96% of PV and 55% of ET and 65% of PMF (Tefferi, 2010). 
High IFN and STAT1 plays a role in promoting ET phenotype in JAK2V617F positive 
MPNs. JAK2V617F mice displayed higher IFN level than non-transgenic mice (Chen et al., 
2010), and JAK2V617F/Stat1+/+ mice had higher megakaryopoiesis and reduced 
erythropoiesis compared to JAK2V617F/Stat1-/- mice (Duek et al., 2014). However, the 
molecular mechanism of IFN/STAT1 in promoting ET phenotype is not well understood. 
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1.5.4 STAT1 in cancer 
Majority of the studies on the role of STAT1 in cancer was done using animal models. 
STAT1 is thought to be tumour suppressive, but recent a study revealed that STAT1 may 
promote tumourigenesis (Meissl et al., 2015). The expression of STAT1 leads to favorable 
prognosis in several cancers, such as hepatocellular carcinoma, breast cancer, colorectal 
carcinoma and pancreatic cancer (Gordziel et al., 2013, Sun et al., 2014). Overexpression 
of STAT1 was found to inhibit proliferation of HepG2 cells (human hepatocellular cancer 
cells) (Chen et al., 2013) while Stat1-/- female mice develop spontaneous mammary 
adenocarcinomas . Furthermore, STAT1-/- mammary cancer cells underwent apoptosis after 
introduction of functional STAT1 (Chan et al., 2012).  
However, STAT1 may also confer promotion to tumour cells. CD95 stimulation of cancer 
cells leads to increased production of Type I IFN, which causes STAT1 activation and 
results in cancer therapy resistance. STAT1 knockdown or knockout cells have reduced 
capability in sustaining the stemness of cancer cells by CD95 ligand and Type I IFN (Qadir 
et al., 2017). In addition, overexpression of STAT1 was found to impair apoptosis via IL-6 
and IL-8 production (Efimova et al., 2009); whereas increased STAT1 and CD74 in triple-
negative breast cancer was shown to promote tumour invasion and metastasis (Greenwood 
et al., 2012).  
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1.6 Aim of study 
Our lab is interested in the JAK-STAT signaling pathway during Type I IFN response. For 
that, we have acquired 2fTGH cells and its derivative U2A, U3A, U5A, U6A cells lines 
(deficient in IRF9, STAT1, STAT2 and IFNAR, respectively from Prof. George Stark 
(Cleveland clinic, USA). My project is a preliminary study aiming to determine the 
feasibility of using U3A cells and restored recombinant STAT1 as a model system for 
STAT1 research. In particular, I need to determine if recombinant STAT1 protein functions 
similarly to endogenous STAT1 protein during Type I IFN response. 
 
1.6.1 General objective 
Plasmid construction and to characterize the function of overexpressed Flag-STAT1B in 
restoring the JAK-STAT signaling pathway in response to Type I IFN, using U3A cells.  
 
1.6.2 Specific objectives 
1) To construct recombinant plasmid expressing Flag-STAT1B by sub-cloning 
STAT1B into p3xFlag-CMVTM-7.1 vector plasmid.  
2) To induce Flag-STAT1B overexpression in U3A cells. 
3) To evaluate the restoration of JAK-STAT signaling pathway in U3A cells, 
expressing Flag-STAT1B when induced by IFN-β.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Preparation of expression plasmids 
2.1.1 Escherichia coli  
2.1.1.1 Escherichia coli strain 
Genotype of TOP 10 Escherichia coli: F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δ lacX74 recA1 araD139 Δ( araleu)7697 galU galK rpsL (StrR) endA1 nupG 
 
2.1.1.2 Bacteria growth medium 
 * Ampicillin (Roscillin®, Ranbaxy Laboratories Limited) 
 * LB AGAR (LENNOX) (Laboratories CONDA; pH 7.0 ± 0.2 at 25 ºC; 15 g 
Bacteriological Agar, 5 g NaCl, 10 g Tryptone, 5 g Yeast Extract) 
 * LB BROTH (LENNOX) (Laboratories CONDA; pH 7.0 ± 0.2 at 25 ºC; 5 g NaCl, 
10 g Tryptone, 5 g Yeast Extract) 
 
Preparation of LB broth:  
For 1 liter of LB broth, 20 g of LB BROTH (LENNOX) was dissolved in distilled water to 
make up to 1 liter. The LB broth was autoclaved before use. It was kept in room 
temperature for further use.   
 
Preparation of LB agar plate with Ampicillin: 
A total 5.25 g of LB AGAR (LENNOX) was dissolved in 150 ml of distilled water, and 
then autoclaved. The LB agar solution was allowed to cool down before 150 µl of 100 mg/l 
Ampicillin was added to a final concentration of 100 µg/ml. The LB agar (with Ampicillin) 
was then poured into petri dish (8- 9 plates) for solidification at room temperature. The 
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process normally took around 40 minutes. Solidified LB agar/Ampicillin plates were sealed 
with parafilm and kept at – 42 ºC until further use.  
 
2.1.1.3 Preparation of Escherichia coli glycerol stock 
One ml of cryopreserved Escherichia coli was inoculated into 9 ml of LB broth and 
incubated overnight at 37 ºC in shaking incubator (INFORS HT Minton) at 200 rpm. 
Overnight bacteria culture, every 200 µl of the Escherichia coli culture was mixed well 
with 100 µl of glycerol and froze in dry ice before stored at – 80 ºC. They were kept as 
cryopreserve Escherichia coli stock.  
 
2.1.1.4 Preparation of competent Escherichia coli 
* CaCl2 (R&M Chemicals) 
 * Glycerol (R&M Chemicals) 
One ml from the overnight bacteria culture (Section 2.1.1.3) was transferred into fresh 100 
ml LB broth to make chemical competent cells. OD of the bacteria culture was measured 
using spectrophotometer (Eppendorf) at wavelength 600 nm until the OD600 reached 
approximately 0.5. At 2 hours incubation in shaking incubator (INFORS HT Minton) at   
37 ºC, the OD600 reading was 0.5598. The 100 ml bacteria culture was splitted into two 50 
ml volume in centrifuge tubes and centrifuged at 4 ºC, 2400 x g for 10 minutes. 
Supernatant was discarded and the pellet was resuspended with pre-chilled 15 ml of 0.1M 
CaCl2. The resuspended bacteria was incubated in ice for 15 minutes before centrifuged 
again at 4 ºC, 2400 x g for 10 minutes were repeated two more times. After the third 
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centrifugation, the bacteria pellet was resuspended in 2 ml of 0.1 M of CaCl2 with 20% (v/v) 
glycerol. Two hundred µl of chemical competent Escherichia coli was aliquoted into each 
pre-chilled microcentrifuge tube and quickly frozen in dry ice. The chemical competent 
cells were stored at – 80 ºC. 
 
2.1.2 Primer Design 
All the primers were ordered from Integrated DNA Technologies. STAT1B specific primers 
are p3xFlag-STAT1B_F (forward primer) and p3xFlag-STAT1B_R (reverse primer).Both 
primers were designed with introduction specific restriction enzyme (RE) site, EcoR1 and 
BamH1 RE site for p3xFlag-STAT1B_F and p3xFlag-STAT1B_R primers respectively. 
These primers will be used in amplification of STAT1B and PCR colony. The customized 
RE site in primers are important for sub-cloning. 
 
2.1.2.1 Oligonucleotides for sub-cloning 
Name Sequence (5’ → 3’) Tm (ºC) 
p3xFlag-STAT1B_F CACTCGAATTCCATGTCTCAGTGGTAC 58.8 
p3xFlag-STAT1B_R CTCGGATCCTTACACTTCAGACACAG 58.4 
 
*Restriction site in Bold 
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2.1.2.2 Oligonucleotides for sequencing 
Name Sequence (5’ → 3’) Tm (ºC) 
CMV_FSP GTAGGCGTGTACGGTGGGAGG 61.8 
STAT1B_FSP409 GACAAACAGAAAGAGCTTGAC 51.8 
STAT1B_FSP3016 CAGAGGCCGCTGGTCTTGAAG 60.4 
STAT1B_FSP3610 GGTCCTAACGCCAGCCCCGAT 64.1 
 
2.1.3 Polymerase chain reaction (PCR) 
* dNTPs (Promega) 
* PCR buffer (Thermo Scientific) 
* Pfu polymerase (Thermo Scientific) 
* Taq polymerase (KAPA Biosystem) 
Polymerase chain reaction was done using MyCycler Thermal Cycler (BIO-RAD). Primers 
specific to a gene will annealed to the complementary DNA sequence of the target gene is 
present in PCR sample. DNA polymerase could then synthesis the complementary strand 
from 5’ to 3’and thus target gene was amplified.  
 
PCR conditions were: 
1.   Initializing step (95 ºC)         300 seconds 
2. (x 30)  Denaturation step (95 ºC)           30 seconds 
      Annealing step (Mentioned in Section 3.1.2.1 and 3.1.2.2)        30 seconds 
      Elongation step (72 ºC)         180 seconds 
3.   Finalizing step (72 ºC)        300 seconds 
4.   Hold (4 ºC)          ∞   
 
20 
 
2.1.3.1 Gradient PCR 
A master mix solution was prepared as appropriate, according to Table 2.1. The 
polymerases were added to the reaction mixture just before PCR. Annealing temperature 
for amplification of STAT1B was optimized by using gradient PCR, in the range of 53 ºC to 
63 ºC. The conditions of gradient PCR was set up as stated in Section 2.1.3. The annealing 
temperatures: 53.0 ºC, 53.7 ºC, 54.9 ºC, 56.7 ºC, 59.1 ºC, 61.0 ºC, 62.2 ºC and 63.9 ºC were 
tested.  
 
Table 2.1: Master mix preparation in gradient PCR 
Components 
Working 
Concentration 
Volume per 
reactions (µl) 
Volume for 9 
reactions (µl) 
PCR buffer (10x) 1x 5 45 
Distilled water 
 
40.86 367.7 
dNTPs (10 mM) 0.2 mM 1 9 
p3xFlag-STAT1B_F (20 µM)  0.4 µM 1 9 
p3xFlag-STAT1B_R (20 µM)  0.4 µM 1 9 
pOTB7-STAT1B (25 ng/µl) 11 ng 0.44 4 
Taq polymerase  0.5 U 0.2 1.8 
Pfu polymerase  1U 0.5 4.5 
Total   50.0 450.0 
 
 
 
 
 
 
 
 
 
